Traumatic brain injury (TBI) impacts over 2.5 million people annually in the US. AivoCode has licensed technology from Sanford Burnham Prebys Medical Discovery Institute (SBP) to improve delivery of therapeutic or an imaging payload from systemic circulation to the injured part of brain. The schematic below demonstrates targeting of an intravenously injected fluorescently labeled peptide to a TBI lesion in mice. Given the limited treatment options for these conditions, our technology has the potential to change the clinical management of TBI.
To read more about this technology please click here.
Alzheimer’s disease (AD) is the most common progressive neurodegenerative disorder associated with aging. Limited success of recent clinical trials of various AD treatments may be attributable to treating the disease too late. AivoCode is developing specific probes that recognize AD signature present in the brain. These probes can be used for therapeutic delivery and non-invasive detection of early AD.
Multiple Sclerosis (MS) is an immune-mediated inflammatory disease affecting brain, nerve and spinal cord tissue that affects over 2 million people. It causes demyelination of neurons, axonal damage, and neurodegeneration. AivoCode’s platform technology is selective to CNS lesions characteristic of MS.
Thought leaders in bioengineering, neuroscience, and drug delivery
By Bradley J. Fikes (San Diego Union Tribune) reporting a potential new way to deliver medications to traumatically injured brains by a team led by scientists at the Sanford B
By Alison Stoddart (Nature Reviews Materials) highlighting the brain injury targeting discovery made by SBP team. View full article below. CLICK HERE
AivoCode’s brain injury technology awarded SBIR phase II grant from NSF in Apr 2017. See more details HERE.